title: [Lambert-Eaton myasthenic syndrome: response to treatment with 3,4-diaminopyridine].
authors.forename: C
authors.initials: C
authors.lastname: Morata
authors.forename: A
authors.initials: A
authors.lastname: Alfaro
authors.forename: M J
authors.initials: MJ
authors.lastname: Chumillas
authors.forename: J
authors.initials: J
authors.lastname: Montalar
mesh_terms: D015761:4-Aminopyridine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000368:Aged; D000077770:Amifampridine; D018288:Carcinoma, Small Cell / Q000150:complications / Q000188:drug therapy; D006801:Humans; D015624:Lambert-Eaton Myasthenic Syndrome / Q000150:complications / Q000188:drug therapy*; D008175:Lung Neoplasms / Q000150:complications / Q000188:drug therapy; D008297:Male; D015221:Potassium Channels; D012074:Remission Induction
chemical_list: D015221:Potassium Channels; D015761:4-Aminopyridine; D000077770:Amifampridine
vernacular_title: Síndrome miasténico de Lambert-Eaton: respuesta al tratamiento con 3,4-diaminopiridina.